Efficacy of TCA Effect on Varicella Atrophic Scars - Full Text View

Efficacy of TCA Effect on Varicella Atrophic Scars

This study is currently recruiting participants.
Verified by Shaheed Beheshti Medical University, January 2007

Sponsored by:	Shaheed Beheshti Medical University
Information provided by:	Shaheed Beheshti Medical University
ClinicalTrials.gov Identifier:	NCT00422539

Purpose

This study aims to determine the efficacy of 70% trichloroacetic acid on atrophic scars of varicella

Condition	Intervention	Phase
Atrophic Varicella Scar	Drug: 70% trichloroacetic acid	Phase II

MedlinePlus related topics:

Chickenpox Scars Shingles

Drug Information available for:

Acetic acid Trichloroacetic acid

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Official Title:	Evaluation of Tri Chloro Acetic Acid (TCA) Effect on Atrophic Varicella Scars

Further study details as provided by Shaheed Beheshti Medical University:

Primary Outcome Measures:

Objective Clearance(before and after photographies were taken)

Secondary Outcome Measures:

Subjective Clearance(according to the patients satisfaction)
Adverse effects(assessed by clinician as erythema, pigmentary changes, scaring)

Estimated Enrollment:	100
Study Start Date:	March 2006

Detailed Description:

high concentration trichloroacetic acid peeling has been shown to be effective in treating and flattening the atrophic acne scars. According to the lack of an effective and low cost therapy for removing these relative common and nuisance lesions; We aimed to answer that whether we could achieve the same results from 70% TCA on atrophic varicella scars.

Eligibility

Ages Eligible for Study:	15 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Atrophic varicella scar on face

Exclusion Criteria:

Active varicella infection
Active Herpetic infection
Previous history of keloid formation

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00422539

Contacts


Contact: Behrooz Barikbin, M.D.	98-21-22744393 ext 5	bbarikbin@yahoo.com

Locations


Iran, Islamic Republic of
	Skin Research Center, Shohada-e Tajrish Hospital, shaheed Beheshti Medical University	Recruiting
	Tehran, Iran, Islamic Republic of, 198994148

Sponsors and Collaborators

Shaheed Beheshti Medical University

Investigators


Study Chair:	Parviz Toossi, M.D.	Skin Research Center of Shaheed Beheshti medical University

Principal Investigator:	Behrooz Barikbin, M.D.	Skin Research Center of Shaheed Beheshti Medical Universty

More Information

Study ID Numbers:	SRC-BBA-1385-6-1
First Received:	January 16, 2007
Last Updated:	January 16, 2007
ClinicalTrials.gov Identifier:	NCT00422539
Health Authority:	Iran: Ministry of Health

Keywords provided by Shaheed Beheshti Medical University:

trichloroacetic acid

varicella scar

Study placed in the following topic categories:

Pathological Conditions, Anatomical

Virus Diseases

Herpes Zoster

Skin Diseases

Chickenpox

DNA Virus Infections

Atrophy

Chicken pox

Herpesviridae Infections

Cicatrix

ClinicalTrials.gov processed this record on October 22, 2008